ACOR News and Press, Acorda Therapeutics Inc. From 11/13/23

2023-11-13 17:43:09 ET Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO ...

2023-11-13 16:04:03 ET More on Acorda Therapeutics Financial information for Acorda Therapeutics For further details see: Acorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72M

INBRIJA ® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA ® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Acorda Therapeutics Inc. (ACOR) is expected to report for Q1 2024

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its third quarter 2023 update and financial results on Monday, November 13 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc....

Up to five approvals expected in 2024 Additional filings expected in Chile in late 2023 and in Mexico and Brazil in 2024 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA ® (levodopa inhalation ...

2023-10-13 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) is one of today's top gainers. The company's shares are currently up 9.09% on the day to $12.22. Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company m...